WHO Recommends Two Additional Ebola Vaccines For Testing In DR Congo
The WHO recommended testing two Ebola vaccines, ChAdOx1 (Oxford/Serum Institute) and mRNA-1469 (Moderna), in the Tumaini trial in DRC. The trial, led by DRC's Institut National de Recherche Biomédicale, aims to evaluate vaccines against the Bundibugyo virus. Investments from CEPI have supported development. Results are expected in early 2027.
How this was made
The 30-second read
Why it matters
The inclusion signals progress in Ebola vaccine pipelines and may influence investor sentiment toward Moderna and the broader biotech space.
Market read
New trial inclusion provides fresh catalyst for Moderna and highlights ongoing vaccine innovation, potentially affecting biotech valuations.
What to watch
Regulatory approvals and manufacturing scale for the candidate remain uncertain.
Background
The WHO is expanding the Tumaini trial to test two new Ebola vaccine candidates, including Moderna's mRNA-1469, during an active outbreak of the Bundibugyo virus in the DRC.
Ticker impact
WHO added Moderna's mRNA-1469 Ebola vaccine candidate to the Tumaini trial in DRC.
likely modest upside as market prices in future trial success potential
The addition of a Moderna candidate to an active outbreak trial is new material, but impact depends on future data.
Market effects
could boost biotech sector sentiment around vaccine development
may raise interest in African health‑care investments
adds to global focus on emerging infectious disease preparedness
Counterpoint
If trial fails, Moderna could face a setback despite the headline news.
Key entities
- CompanyModerna
Developer of the mRNA-1469 Ebola vaccine candidate.
- OrganizationWorld Health Organization
Recommended the addition of the new vaccine candidates to the trial.
